Barclays PLC Annexon, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Annexon, Inc. stock. As of the latest transaction made, Barclays PLC holds 177,765 shares of ANNX stock, worth $936,821. This represents 0.0% of its overall portfolio holdings.

Number of Shares

177,765

Previous 177,765 -0.0%

Holding current value

$936,821

Previous $1.05 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$4.49 - $7.2 $542,342 - $869,680	120,789 Added 212.0%	177,765 $1.05 Million
Q2 2024 Aug 14, 2024	SELL	$4.33 - $6.79 $77,610 - $121,703	-17,924 Reduced 23.93%	56,976 $279,000
Q1 2024 May 15, 2024	SELL	$4.03 - $7.81 $445,036 - $862,466	-110,431 Reduced 59.59%	74,900 $536,000
Q4 2023 Feb 15, 2024	BUY	$1.63 - $4.63 $243,847 - $692,648	149,600 Added 418.68%	185,331 $841,000
Q3 2023 Nov 07, 2023	SELL	$2.13 - $3.84 $6,375 - $11,493	-2,993 Reduced 7.73%	35,731 $84,000
Q2 2023 Aug 03, 2023	SELL	$2.1 - $6.37 $61,536 - $186,660	-29,303 Reduced 43.08%	38,724 $135,000
Q1 2023 May 04, 2023	BUY	$3.74 - $7.46 $129,632 - $258,571	34,661 Added 103.88%	68,027 $263,000
Q4 2022 Feb 13, 2023	BUY	$4.56 - $6.61 $114,031 - $165,296	25,007 Added 299.16%	33,366 $172,000
Q3 2022 Nov 03, 2022	BUY	$3.75 - $6.63 $4,961 - $8,771	1,323 Added 18.8%	8,359 $51,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $4.06 $10,906 - $20,986	-5,169 Reduced 42.35%	7,036 $27,000
Q1 2022 May 16, 2022	BUY	$2.73 - $11.94 $33,319 - $145,727	12,205 New	12,205 $33,000

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $251M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account